TÀI LIỆU THAM KHẢO
1. Foidart, J.-M., Wuttke, W., Bouw, G. M., Gerlinger, C., & Heithecker, R. (2000). A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. The European Journal of Contraception & Reproductive Health Care, 5(2), 124–134. doi:10.1080/13625180008500387
2. Burkman, R., Schlesselman, J. J., & Zieman, M. (2004). Safety concerns and health benefits associated with oral contraception. American Journal of Obstetrics and Gynecology, 190(4), S5–S22.
3. Casado-Espada, N. M., de Alarcón, R., de la Iglesia-Larrad, J. I., Bote-Bonaechea, B., & Montejo, Á. L. (2019). Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. Journal of Clinical Medicine, 8(6), 908. doi:10.3390/jcm8060908
4. (2005). Noncontraceptive health benefits of combined oral contraception. Human Reproduction Update, 11(5), 513–525. doi:10.1093/humupd/dmi019
5. Schindler, A. E. (2012). Non-Contraceptive Benefits of Oral Hormonal Contraceptives. International Journal of Endocrinology and Metabolism, 11(1). doi:10.5812/ijem.4158
6. Oelkers, W. (1995). Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology & Metabolism, 80(6), 1816–1821. doi:10.1210/jc.80.6.1816
7. Chumpalova, P., Iakimova, R., Stoimenova-Popova, M., Aptalidis, D., Pandova, M., Stoyanova, M., & Fountoulakis, K. N. (2020). Prevalence and clinical picture of premenstrual syndrome in females from Bulgaria. Annals of General Psychiatry, 19(1). doi:10.1186/s12991-019-0255-1
8. Klipping, C., Duijkers, I., Trummer, D., & Marr, J. (2008). Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception, 78(1), 16–25. doi:10.1016/j.contraception.2008.02.019
9. Willis, S. A., Kuehl, T. J., Spiekerman, A. M., & Sulak, P. J. (2006). Greater inhibition of the pituitary–ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception, 74(2), 100–103. doi:10.1016/j.contraception.2006.02.006
10. Beral, V., Doll, R., Hermon, C. (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls. The Lancet, 371(9609), 303–314. doi:10.1016/s0140-6736(08)60167-1
11. Tsilidis, K. K., Allen, N. E., Key, T. J., Dossus, L., Lukanova, A., Bakken, K., … Riboli, E. (2011). Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. British Journal of Cancer, 105(9), 1436–1442. doi:10.1038/bjc.2011.371
12. WHO : BMJ. 2002 Apr 6; 324(7341): 808.doi: 10.1136/bmj.324.7341.808/a. PMCID: PMC1122763. PMID: 11934771. WHO links long term pill use to cervical cancer Owen Dyer)
13. Ellen M Mikkelsen , Anders H Riis, Lauren A Wise, Elizabeth E Hatch, Kenneth J Rothman, Henrik Toft Sorensen.(2013). Pre-gravid oral contraceptive use and time to pregnancy: a Danish prospective cohort study
